$NWBO
NORTHWEST BIOTHERAPEUTICS INC

2022 Q2 Form 10-Q Financial Statement

#000141057822001218 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $477.0K $403.0K $0.00
YoY Change 14.66% 68.62% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.931M $7.869M $6.490M
YoY Change 7.58% -38.93% -56.62%
% of Gross Profit
Research & Development $13.65M $4.820M $4.186M
YoY Change 150.32% -30.38% -52.97%
% of Gross Profit
Depreciation & Amortization $524.0K $100.0K $84.00K
YoY Change 580.52% 47.06% 55.56%
% of Gross Profit
Operating Expenses $21.58M $4.820M $10.68M
YoY Change 295.82% -30.38% -55.26%
Operating Profit -$21.10M -$12.29M
YoY Change 70.06% -37.22%
Interest Expense -$8.459M $1.903M $144.4M
YoY Change -1148.2% 31.51% -155.6%
% of Operating Profit
Other Income/Expense, Net -$8.569M -$1.928M -$333.0K
YoY Change -150.95% -112.48%
Pretax Income -$29.67M -$14.21M $133.3M
YoY Change -772.74% 244.75% -147.56%
Income Tax
% Of Pretax Income
Net Earnings -$29.67M -$14.20M $133.3M
YoY Change -772.74% 244.41% -147.56%
Net Earnings / Revenue -6219.71% -3523.57%
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share -$29.55K -$0.01 $143.2K
COMMON SHARES
Basic Shares Outstanding 984.2M 959.3K 0.000
Diluted Shares Outstanding 1.004M 959.3K

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.831M $6.963M $15.17M
YoY Change 28.55% -6.76% 51.95%
Cash & Equivalents $4.831M $6.963M $15.17M
Short-Term Investments
Other Short-Term Assets $2.347M $2.306M $2.121M
YoY Change -48.88% -59.89% -61.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.178M $9.269M $17.29M
YoY Change -14.03% -29.87% 11.47%
LONG-TERM ASSETS
Property, Plant & Equipment $18.08M $14.39M $15.03M
YoY Change 1278.28% 1065.72% 1344.9%
Goodwill $626.0K $626.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $342.0K $349.0K $1.036M
YoY Change -68.71% -67.38% 19.49%
Total Long-Term Assets $20.34M $21.39M $22.87M
YoY Change -0.37% 11.15% 31.53%
TOTAL ASSETS
Total Short-Term Assets $7.178M $9.269M $17.29M
Total Long-Term Assets $20.34M $21.39M $22.87M
Total Assets $27.52M $30.66M $40.16M
YoY Change -4.33% -5.55% 22.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.03M $10.64M $10.95M
YoY Change 23.64% 1.91% -14.07%
Accrued Expenses $329.0K $325.0K $317.0K
YoY Change 32.13% 91.18% 89.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.993M $12.12M $7.239M
YoY Change 30.54% 410.4% 15.51%
Total Short-Term Liabilities $98.16M $130.0M $133.8M
YoY Change -72.79% -64.22% -65.02%
LONG-TERM LIABILITIES
Long-Term Debt $16.45M $16.16M $25.16M
YoY Change 32.76% -3.16% 195.71%
Other Long-Term Liabilities $4.574M $5.008M $5.226M
YoY Change -16.93% -9.93% 6.31%
Total Long-Term Liabilities $21.03M $21.17M $30.38M
YoY Change 17.47% -4.85% 126.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $98.16M $130.0M $133.8M
Total Long-Term Liabilities $21.03M $21.17M $30.38M
Total Liabilities $119.2M $151.2M $164.2M
YoY Change -68.52% -60.8% -58.53%
SHAREHOLDERS EQUITY
Retained Earnings -$1.206B -$1.192B
YoY Change -12.29% -13.06%
Common Stock $1.085B $1.068B
YoY Change 6.06% 5.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$91.67M -$120.5M -$124.0M
YoY Change
Total Liabilities & Shareholders Equity $27.52M $30.66M $40.16M
YoY Change -4.33% -5.55% 22.07%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$29.67M -$14.20M $133.3M
YoY Change -772.74% 244.41% -147.56%
Depreciation, Depletion And Amortization $524.0K $100.0K $84.00K
YoY Change 580.52% 47.06% 55.56%
Cash From Operating Activities -$14.84M -$12.97M -$11.25M
YoY Change 118.51% -2.12% 10.22%
INVESTING ACTIVITIES
Capital Expenditures -$408.0K -$58.00K -$1.553M
YoY Change -72.93% -78.03% -49.28%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$408.0K -$58.00K -$1.553M
YoY Change -72.93% -78.03% -48.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.41M 3.920M 23.67M
YoY Change 117.76% -63.57% 49.62%
NET CHANGE
Cash From Operating Activities -14.84M -12.97M -11.25M
Cash From Investing Activities -408.0K -58.00K -1.553M
Cash From Financing Activities 10.41M 3.920M 23.67M
Net Change In Cash -4.838M -8.206M 10.87M
YoY Change 37.52% 226.28% 320.87%
FREE CASH FLOW
Cash From Operating Activities -$14.84M -$12.97M -$11.25M
Capital Expenditures -$408.0K -$58.00K -$1.553M
Free Cash Flow -$14.43M -$12.91M -$9.693M
YoY Change 173.09% -0.58% 35.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001072379
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NONE
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
948400000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
969700000
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-35737
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
NORTHWEST BIOTHERAPEUTICS, INC
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3306718
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4800 Montgomery Lane
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19570000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
540000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17563000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
410000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8000
CY2022Q1 us-gaap Interest Expense
InterestExpense
1903000
CY2021Q1 us-gaap Interest Expense
InterestExpense
1447000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-975000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-661000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1928000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15447000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14214000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4123000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-808000
CY2021Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
9818000
CY2022Q1 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
636000
CY2021Q1 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-6450000
CY2022Q1 nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
199000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-624000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13406000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3499000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
959251
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
834605
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
959251
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
834605
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-123991000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3364000
CY2022Q1 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
4185000
CY2022Q1 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
7715000
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
CY2022Q1 dei City Area Code
CityAreaCode
240
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
497-9024
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
NWBO
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
984247092
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6963000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15169000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2306000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2121000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
9269000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
17290000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14385000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15027000
CY2022Q1 nwbo Constructions In Progress Net
ConstructionsInProgressNet
28000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4709000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4889000
CY2022Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2022Q1 us-gaap Goodwill
Goodwill
626000
CY2021Q4 us-gaap Goodwill
Goodwill
626000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
349000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1036000
CY2022Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
21389000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
22870000
CY2022Q1 us-gaap Assets
Assets
30658000
CY2021Q4 us-gaap Assets
Assets
40160000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7726000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6976000
CY2022Q1 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
2918000
CY2021Q4 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
3971000
CY2022Q1 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
135000
CY2021Q4 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
135000
CY2022Q1 us-gaap Notes Payable Current
NotesPayableCurrent
11982000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7104000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8308000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8232000
CY2022Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
98618000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
106784000
CY2021Q1 nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
286000
CY2022Q1 nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
4000
CY2022Q1 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
987000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
617000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14214000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
808000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-120525000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-362948000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16000
CY2021Q1 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
6619000
CY2021Q1 nwbo Value Of Warrants And Stock Options Exercised For Cash
ValueOfWarrantsAndStockOptionsExercisedForCash
745000
CY2021Q1 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
2935000
CY2021Q1 nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
146000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9891000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4123000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
624000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-353200000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14214000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4123000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
68000
CY2022Q1 nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
809000
CY2021Q1 nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
1126000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
540000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
17563000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
410000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8000
CY2022Q1 nwbo Operating Lease Roa
OperatingLeaseRoa
60000
CY2021Q1 nwbo Operating Lease Roa
OperatingLeaseRoa
93000
CY2022Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
617000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
325000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
317000
CY2021Q4 nwbo Shares Payable Current
SharesPayableCurrent
250000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
130012000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
133769000
CY2022Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
16163000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25156000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5008000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5226000
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
21171000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
30382000
CY2022Q1 us-gaap Liabilities
Liabilities
151183000
CY2021Q4 us-gaap Liabilities
Liabilities
164151000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
969700000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
948400000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
970000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
948000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1083723000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1066873000
CY2022Q1 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2021Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1206304000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1192090000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1165000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
357000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-120525000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-123991000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30658000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40160000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
403000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
239000
CY2022Q1 us-gaap Revenues
Revenues
403000
CY2021Q1 us-gaap Revenues
Revenues
239000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4820000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6923000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7869000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12886000
CY2022Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12689000
CY2021Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
19809000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12286000
CY2022Q1 nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
-679000
CY2021Q1 nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
198000
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
795000
CY2021Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
876000
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-694000
CY2021Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-3128000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
30000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
61000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12967000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13248000
CY2022Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
58000
CY2021Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
264000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-264000
CY2022Q1 nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
3140000
CY2021Q1 nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
16000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4185000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
745000
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
600000
CY2021Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4005000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3920000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10761000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
899000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
236000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8206000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2515000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15169000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9983000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6963000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7468000
CY2021Q1 nwbo Stock Issued During Period Value For Warrant And Stock Options Cashless Exercise
StockIssuedDuringPeriodValueForWarrantAndStockOptionsCashlessExercise
5000
CY2022Q1 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
7715000
CY2021Q1 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
2935000
CY2022Q1 nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
4000
CY2021Q1 nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
146000
CY2021Q1 nwbo Reclassification Of Warrant Liabilities Based On Authorized Shares
ReclassificationOfWarrantLiabilitiesBasedOnAuthorizedShares
7105000
CY2022Q1 nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
987000
CY2021Q1 nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
6742000
CY2022Q1 nwbo Reclassification Between Shares Payable And Equity
ReclassificationBetweenSharesPayableAndEquity
250000
CY2022Q1 nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
86000
CY2021Q1 nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
753000
CY2022Q1 nwbo Capital Expenditures Included In Accounts Payable And Accrued Expenses To Related Parties And Affiliates
CapitalExpendituresIncludedInAccountsPayableAndAccruedExpensesToRelatedPartiesAndAffiliates
11000
CY2022Q1 nwbo Capitalized Cost Amortization
CapitalizedCostAmortization
28000
CY2021Q1 nwbo Capitalized Cost Amortization
CapitalizedCostAmortization
700000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4200000
CY2022Q1 nwbo Stock Issued During Period Shares Warrant Exercises
StockIssuedDuringPeriodSharesWarrantExercises
15300000
CY2022Q1 us-gaap Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
true
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5300000
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P20Y
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
225469
CY2021Q4 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.30
CY2021 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P0Y11M15D
CY2022Q1 nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
15256
CY2022Q1 nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
0.27
CY2022Q1 nwbo Number Of Warrants Warrants Cashless Exercise
NumberOfWarrantsWarrantsCashlessExercise
56
CY2022Q1 nwbo Weighted Average Exercise Price Warrants Cashless Exercise
WeightedAverageExercisePriceWarrantsCashlessExercise
0.52
CY2022Q1 nwbo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
1452
CY2022Q1 nwbo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
0.0191
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
208705
CY2022Q1 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.29
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14200000
CY2022Q1 us-gaap Payments For Operating Activities
PaymentsForOperatingActivities
13000000.0
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic (“COVID-19”) and the COVID-19 control responses.</span></p>
CY2022Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
98618000
CY2022Q1 nwbo Embedded Derivative Redemption Option Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeRedemptionOptionFairValueOfEmbeddedDerivativeLiability
978000
CY2022Q1 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8308000
CY2022Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
107904000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
106784000
CY2021Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
988000
CY2021Q4 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8232000
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
116004000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
116004000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
159000
CY2022Q1 nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash
7719000
CY2022Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-540000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
107904000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
617000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9818000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.77
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.95
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.014
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1600000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
304847
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
114803000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.77
CY2022Q1 nwbo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P10Y
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4700000
CY2022Q1 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P0Y9M25D
CY2022Q1 nwbo Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsIntrinsicValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
304867
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
114803000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
284728
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.32
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
108032000
CY2022Q1 nwbo Share Based Compensation Arrangement By Share Based Payment Award Period Of Notice For Exercising Any Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodOfNoticeForExercisingAnyOption
P61D
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
30465000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3163000
CY2022Q1 nwbo Fair Value Of Embedded Conversion Option
FairValueOfEmbeddedConversionOption
978000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
28280000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
35243000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3836000
CY2021Q4 nwbo Fair Value Of Embedded Conversion Option
FairValueOfEmbeddedConversionOption
988000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
32395000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
513648000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
631438000
CY2021Q3 nwbo Extended Term Of Agreement
ExtendedTermOfAgreement
P12M
CY2022Q3 nwbo Extended Term Of Agreement
ExtendedTermOfAgreement
P12M
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
36000
CY2022Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
2800000
CY2021Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
1700000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
152000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
13000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
10000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
36000
CY2022Q1 us-gaap Lease Cost
LeaseCost
139000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
239000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
246000
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
53000
CY2021Q1 us-gaap Lease Cost
LeaseCost
311000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
255000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
711000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
956000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
862000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
657000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
657000
CY2022Q1 nwbo Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
7860000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11703000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6370000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5333000
CY2022Q1 nwbo Original Term Of Agreement
OriginalTermOfAgreement
P8M
CY2022Q1 nwbo Extended Term Of Agreement
ExtendedTermOfAgreement
P12M
CY2021Q4 nwbo Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
7700000
CY2021Q4 nwbo Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
7700000
CY2021Q4 nwbo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2000000.0
CY2021Q4 nwbo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2000000.0

Files In Submission

Name View Source Status
0001410578-22-001218-index-headers.html Edgar Link pending
0001410578-22-001218-index.html Edgar Link pending
0001410578-22-001218.txt Edgar Link pending
0001410578-22-001218-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nwbo-20220331.xsd Edgar Link pending
nwbo-20220331x10q.htm Edgar Link pending
nwbo-20220331x10q_htm.xml Edgar Link completed
nwbo-20220331xex31d1.htm Edgar Link pending
nwbo-20220331xex32d1.htm Edgar Link pending
nwbo-20220331_cal.xml Edgar Link unprocessable
nwbo-20220331_def.xml Edgar Link unprocessable
nwbo-20220331_lab.xml Edgar Link unprocessable
nwbo-20220331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending